Total
0
Shares
Incannex Healthcare (ASX:IHL) - Chief Medical Officer, Dr Sud Agarwal (left) & CEO, Joel Latham (right) - The Market Herald
Chief Medical Officer, Dr Sud Agarwal (left) & CEO, Joel Latham (right)
Source: The Australian
  • Medicinal cannabis company Incannex Healthcare (IHL) has received ethics approval for a phase 2b clinical trial investigating its obstructive sleep apnoea (OSA) treatment
  • OSA occurs when the airway at the back of the throat becomes blocked — when this occurs, loud snoring and choking noises are made
  • As a result, the brain and body become oxygen deprived and the sleeper may wake up multiple times throughout the night
  • The upcoming trial will assess the therapeutic benefit of Incannex's IHL-42X treatment at three different dose levels
  • The primary endpoint will be a reduction in the apnoea hypopnea index (AHI) compared to the baseline level
  • Incannex is up 5.45 per cent on the market and shares are trading for 5.8 cents each

Medicinal cannabis company Incannex Healthcare (IHL) has received ethics approval for a phase 2b clinical trial investigating its obstructive sleep apnoea (OSA) treatment.

OSA occurs when the airway at the back of the throat becomes blocked. When this occurs, loud snoring and choking noises are made.

As a result, the brain and body become oxygen deprived and the sleeper may wake up multiple times throughout the night. This can cause high blood pressure, heart disease, stroke, depression, and diabetes.

Current treatments include weight loss, changing the sleeping position, surgery, and continuous positive airway pressure (CPAP).

The upcoming trial, which will be randomised, double-blind and placebo-controlled, will assess the therapeutic benefit of Incannex's IHL-42X treatment at three different dose levels.

The primary endpoint will be a reduction in the apnoea hypopnea index (AHI) compared to the baseline leven.

The trial will take place at the Alfred Hospital in Melbourne under the supervision of principal investigator Terry O'Brien and contact research origination Novotech.

Patient enrolment will occur in the near future.

"The receipt of ethics approval to commence our first in-human clinical trial is a significant milestone for Incannex," CEO and Managing Director Joel Latham commented.

"A successful drug treatment would be a paradigm shift in obstructive sleep apnoea considering low patient compliance to the current standard of care, the CPAP device," he said.

Incannex is up 5.45 per cent and shares are trading for 5.8 cents at 10:51 am AEST.


Subscribe


IHL by the numbers
More From The Market Herald
EVE Investment (ASX:EVE) - Managing Director, Bill Fry - The Market Herald

" EVE Investments (ASX:EVE) increases revenue and cash balance in Q1 FY21

Wellness business EVE Investments (EVE) has announced a record start to FY21, increasing both its revenue and cash balance during the September quarter.
Holista Colltech (ASX:HCT) - Managing Director, Dr Rajen Manicka - The Market Herald

" Holista CollTech’s (ASX:HCT) Path-Away kills 99.9pc of COVID-19

The coronavirus rollercoaster continues for small-cap biotech company Holista CollTech (HCT) today, with its share price almost doubling on the company’s latest announcement.
Imagion Biosystems (ASX:IBX) appoints Geoff Hollis as CFO

" Imagion Biosystems (ASX:IBX) appoints Geoff Hollis as CFO

Imagion Biosystems (IBX) has appointed Geoff Hollis as its new Chief Financial Officer (CFO).
Anteris Technologies (ASX:AVR) - CEO, Wayne Paterson - The Market Herald

" Anteris Technologies (ASX:AVR) one step closer to biologic heart valve

Anteris Technologies (AVR) is continuing to make progress in the development of its DurAVR 3D single-piece aortic valve.